我是 LongbridgeAI，我可以总结文章信息。Regenxbio (RGNX) 定于 8 月 6 日市场开盘前公布 2026 年第二季度财报。共识预期每股收益（EPS）为-0.11 美元，收入为 9646 万美元，同比增长 352.9%。分析师情绪近期转为负面，过去三个月 EPS 预期经历了一次上调和三次下调，而收入预期则经历了五次下调，没有上调
Regenxbio (RGNX) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $96.46M (+352.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue estimates have seen 0 upward revisions and 5 downward. ...